[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100487198":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":12,"locations":18,"responsibleParty":37,"collaborators":7,"id":40,"slug":41,"hasResults":42,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":7,"enrollmentInfo":51,"targetDuration":7,"studyType":54,"phases":7,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":20,"whyStopped":7,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Aalborg University Hospital","OTHER",null,[9],{"name":10,"affiliation":5,"role":11},"Weronika Szejniuk, MD, PhD","PRINCIPAL_INVESTIGATOR",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Borgen Dalsgaard","CONTACT","97606989","anbd@rn.dk",[19],{"facility":5,"status":20,"city":21,"state":22,"zip":23,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"RECRUITING","Aalborg","Region North Jutland","9000","Denmark","DK",{"type":27,"coordinates":28},"Point",[29,30],9.9187,57.048,{"lat":30,"lon":29},[33],{"name":34,"role":15,"phone":35,"phoneExt":7,"email":36},"Weronika Maria Szejniuk, MD, PhD","97661524","wms@rn.dk",{"type":11,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Weronika Maria Szejniuk","MD, PhD","100487198","proteomics-in-small-cell-lung-cancer-100487198",false,"NCT05623956","Proteomics in Small Cell Lung Cancer","Circulating Metabolites and Tumor-derived Extravesicular Proteins in Small Cell Lung Cancer","SCLC-OMICS","Inclusion Criteria:\n\n* Written and signed informed consent\n* Histopathologically and\u002For cytologically newly-diagnosed SCLC\n* Measurable disease on CT scans\n* Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide\n\nExclusion Criteria:\n\n* Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ\n* Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ\n* Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)\n* Treatment with any other investigational agent",true,"ALL","18 Years",{"count":52,"type":53},50,"ESTIMATED","OBSERVATIONAL","The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.",[57],"Small Cell Lung Cancer",[59,60],"Proteomics","Biomarkers","2025-01-28",{"date":63,"type":64},"2025-01-31","ACTUAL",{"date":66,"type":64},"2023-03-01",{"date":68,"type":53},"2025-12",{"name":5,"class":6},1]